Total Value Creation
₹18-28 Cr
Annualized EBITDA impact
Revenue Uplift
₹25-42 Cr
ARPOB + conversion + mix
Cost Takeout
₹10-16 Cr
People + vendor + capex
EBITDA Margin
19%→22%
+300 bps by Day 100
Workstreams
9
3 phases · 14 weeks
Execution Risk
AMBER
Doctor economics = key risk
💡 The Efficiency Thesis
LHRC is a debt-free, ₹500 Cr revenue hospital at 19% EBITDA. The opportunity is to unlock operating leverage. With ₹131 Cr in fixed costs and 65% fixed cost ratio, every ₹1K ARPOB increase at 570 beds = ₹21 Cr revenue flowing at 35%+ incremental margin. The plan simultaneously tightens the cost base (₹10-16 Cr) while accelerating revenue (₹25-42 Cr) — a twin-engine value creation model. The ₹300 Cr capex transformation (spine robotics, oncology, cathlab) is protected and accelerated.
Value Creation Waterfall — ₹ Crore (Annualized)
Revenue uplift (green) + Cost savings (navy) = Total EBITDA impact
Workstream Scorecard — RAG Status
Weekly review cadence
| Workstream | Status | ₹ Cr |
|---|
| Vendor Consolidation | On Track | 1.5-2.0 |
| Capex Freeze | On Track | 2.0-3.5 |
| Energy & Procurement | Planning | 0.5-1.5 |
| Doctor Fee Reform | At Risk | 2.0-4.0 |
| Staffing Productivity | Planning | 3.0-4.0 |
| Increment Reform | Planning | 1.0-2.0 |
| ARPOB Growth | Planning | 5.0-8.0 |
| OPD→IPD Conversion | Planning | 2.0-3.0 |
| Digital / Oracle Health | Not Started | 1.0-2.0 |
| TOTAL | | 18.0-28.0 |
Baseline vs Day 100 Targets
Transformation Protected
Clinical Capex
₹99 Cr
100% protected
New Doctor Hires
41
On revised fee model
Spine Robotics
₹12 Cr
Kerala's first
FY29 Target
₹780 Cr
Unchanged
FY26 Revenue
₹500 Cr
Baseline
Revenue Uplift
+₹25-42 Cr
ARPOB + volume + mix
Cost Savings
-₹10-16 Cr
People + vendor + capex
EBITDA Impact
+₹18-28 Cr
Net value creation
New EBITDA
₹113-123 Cr
From ₹95 Cr base
Margin Expansion
+250-350 bps
19.0% → 21.5-22.5%
P&L Impact Bridge — FY26 Baseline to Day-100 Run-Rate (₹ Crore)
Current EBITDA + Revenue initiatives + Cost initiatives = Target EBITDA
Revenue Impact Decomposition
Where the ₹25-42 Cr revenue uplift comes from
| Initiative | Conservative | Optimistic | Mechanism | Phase |
|---|
| ARPOB growth ₹49K→53K | ₹15 Cr | ₹21 Cr | Complex care case mix shift | P3 |
| Occupancy lift 62%→65% | ₹5 Cr | ₹8 Cr | Bed management + new depts | P3 |
| OPD→IPD conversion +1% | ₹3 Cr | ₹5 Cr | Patient follow-up CRM | P3 |
| Insurance mix 26%→28% | ₹1 Cr | ₹3 Cr | TPA empanelment + packaging | P2-3 |
| Revenue leakage plug | ₹1 Cr | ₹3 Cr | Unbilled, underpriced, missed | P2 |
| Doctor activation (next 10) | ₹0 Cr | ₹2 Cr | Volume targets for emerging docs | P3 |
| Total Revenue Uplift | ₹25 Cr | ₹42 Cr | | |
Cost Savings Decomposition
Where the ₹10-16 Cr cost takeout comes from
| Initiative | Conservative | Optimistic | Mechanism | Phase |
|---|
| Staffing productivity | ₹3.0 Cr | ₹4.0 Cr | Attrition-based right-sizing | P2 |
| Doctor fee restructure | ₹2.0 Cr | ₹4.0 Cr | New hire model + bottom-Q | P2 |
| Capex deferrals | ₹2.0 Cr | ₹3.5 Cr | Non-clinical freeze | P1 |
| Vendor consolidation | ₹1.5 Cr | ₹2.0 Cr | HK vendor renegotiation | P1 |
| Increment reform | ₹1.0 Cr | ₹2.0 Cr | Performance-linked, doc cap 7% | P2 |
| Energy & procurement | ₹0.5 Cr | ₹1.5 Cr | HVAC, formulary, JIT | P1 |
| Total Cost Savings | ₹10 Cr | ₹16 Cr | | |
EBITDA Margin Walk — Historical to Target (%)
8-year context: FY18 (8.8%) → FY25 (19.4%) → Day 100 (21.5-22.5%) → FY29 (24%)
Current ARPOB
₹49K
Blended · IP: ₹35,188
Target ARPOB
₹53K
Day 100 · +8.2%
IP Revenue
₹267 Cr
74.3% of total YTD
OP Revenue
₹92 Cr
25.7% · OP→IP conversion lever
Insurance Mix
26%
Target: 28%
Concentration Risk
Top 2 = 21%
Down from 27.4% FY24
Revenue Strategy — Operating Leverage is the Prize
With 65% fixed cost ratio, revenue growth falls through to EBITDA at 35%+ incremental margin. Every ₹1K ARPOB increase = ₹21 Cr revenue. The plan targets 3 revenue engines: ARPOB growth via complex care mix, volume growth via occupancy and conversion, payor mix optimisation via insurance expansion. Combined: ₹25-42 Cr incremental revenue.
ARPOB Growth Trajectory (₹K/day)
Case mix shift drives value per bed per day
Volume & Conversion Drivers
IP discharges + occupancy improvement
Department-Level Revenue Acceleration Targets
Top 10 departments with 100-day growth targets aligned to transformation thesis
| # | Department | FY25 ₹Cr | FY26 YTD | Day 100 | Uplift | Lever | Priority |
|---|
| 1 | Orthopaedics | 54.2 | 48.1 | 58.0 | +7% | Spine robotics launch | CORE |
| 2 | GI Surgery | 42.8 | 38.5 | 46.0 | +7% | Liver transplant expansion | CORE |
| 3 | Cardiology | 38.5 | 35.2 | 42.0 | +9% | Biplane cathlab | CORE |
| 4 | Medical Oncology | 28.6 | 26.3 | 32.0 | +12% | 6 new oncologists + tomotherapy | TRANSFORM |
| 5 | Neurosurgery | 26.4 | 24.1 | 28.0 | +6% | CUSA + neuro OT upgrade | GROW |
| 6 | Nephrology | 22.1 | 19.8 | 24.0 | +9% | Renal transplant centre | GROW |
| 7 | Plastic Surgery | 19.4 | 17.2 | 20.0 | +3% | Cosmetic + reconstructive mix | MAINTAIN |
| 8 | Pulmonology | 16.8 | 15.1 | 17.5 | +4% | Sleep lab + bronchoscopy | MAINTAIN |
| 9 | Critical Care | 15.2 | 14.0 | 17.0 | +12% | ICU consolidation + 10 hires | TRANSFORM |
| 10 | Haematology/BMT | 8.4 | 8.0 | 11.0 | +31% | BMT program launch | TRANSFORM |
🏃 14-Week Sprint — 9 Workstreams · 3 Phase Gates
Each workstream has a named owner and weekly KPI tracked at the Tuesday review. Phase gates at Day 30, 60, and 100 require formal sign-off before the next phase commences.
Sprint Gantt — Workstream Timeline
Green = Phase 1 · Orange = Phase 2 · Purple = Phase 3
Week-by-Week Milestone Matrix
Key deliverables · Cumulative savings · Phase gates highlighted
| Week | Day | Phase | Key Milestones | Savings | Gate |
|---|
| W1 | 1-7 | P1 | Vendor audit, capex freeze order, energy audit RFP | — | |
| W2 | 8-14 | P1 | HK RFP issued, non-clinical POs frozen (₹3.95 Cr), procurement benchmarking | ₹2.0 Cr | |
| W3 | 15-21 | P1 | Vendor negotiations, energy interim findings, F&B analysis | ₹0.5 Cr | |
| W4 | 22-30 | P1 | Vendor contracts signed, capex committee live, energy quick-wins | ₹1.5 Cr | DAY 30 |
| W5 | 31-37 | P2 | Doctor fee model finalised, hiring freeze, increment policy drafted | — | |
| W6 | 38-44 | P2 | First 10 hires on revised model, bottom-Q list, shift study begins | ₹0.5 Cr | |
| W7 | 45-51 | P2 | Cross-training launched, increment policy approved, visiting share cap | ₹1.0 Cr | |
| W8 | 52-60 | P2 | 50 FTEs absorbed, Oracle Health Phase 1 kicked off, all P2 savings locked | ₹3.0 Cr | DAY 60 |
| W9-10 | 61-74 | P3 | Oncology OPD launched, spine robotics installation, TPA outreach, CRM pilot | ₹1.0 Cr | |
| W11-12 | 75-88 | P3 | Revenue leakage fixed, ARPOB tracking ₹51K+, ICU design done, doctor targets | ₹3.5 Cr | |
| W13-14 | 89-100 | P3 | Oracle billing live, all revenue initiatives measurable, final report prepared | ₹5.0 Cr | |
| CUMULATIVE ANNUALISED SAVINGS | ₹18.0 Cr | DAY 100 |
🔮 Three-Scenario Financial Model
Base case assumes 70% execution success across all workstreams. Upside assumes 90% with faster ARPOB gains. Downside assumes 50% with doctor economics reform delayed.
DOWNSIDE
₹12 Cr
EBITDA impact · 50% execution
BASE CASE
₹23 Cr
EBITDA impact · 70% execution
UPSIDE
₹34 Cr
EBITDA impact · 90% execution
Scenario Comparison — Pro Forma FY27 P&L (₹ Crore)
Three scenarios against FY26E baseline
| Line Item | FY26E | Downside | Base | Upside | Assumption |
|---|
| Revenue | 500 | 515 | 535 | 555 | ARPOB + volume + mix |
| IP Revenue | 371 | 382 | 398 | 415 | ARPOB ₹51K / 53K / 55K |
| OP Revenue | 129 | 133 | 137 | 140 | OP volume + pricing |
| People Cost | (202) | (198) | (194) | (189) | Staffing + doc fee + increment |
| Other OpEx | (183) | (182) | (180) | (177) | Procurement + energy |
| Capex (Cash) | (130) | (128) | (127) | (126) | Non-clinical deferrals |
| EBITDA | 95 | 107 | 118 | 129 | |
| EBITDA Margin % | 19.0% | 20.8% | 22.1% | 23.2% | +180 / +310 / +420 bps |
Scenario EBITDA Comparison
FY26 baseline vs three scenarios
Sensitivity — ARPOB vs EBITDA
Every ₹1K ARPOB = ₹21 Cr revenue = ~₹7 Cr EBITDA
⚠️ Risk Assessment — 5 Critical, 3 Moderate, 2 Low
The dominant risk is doctor economics reform pushback — ₹99 Cr in doctor cost (49% of people cost). Mitigation: phase implementation, start with new hires only. Second risk: key person dependency — top 2 doctors = 20.7% of revenue.
Risk Heat Map — Impact vs Likelihood
Bubble size = financial exposure
Risk Register — Full Detail
| # | Risk | Category | Impact | Likelihood | RAG | Mitigation | Owner |
|---|
| 1 | Doctor pushback on fee restructure | Commercial | ₹4 Cr | High | CRITICAL | New hires only first; preserve incumbents; EBITDA-bonus carrot | CEO |
| 2 | Key person attrition (top 2) | Commercial | ₹40 Cr | Low | CRITICAL | Retention packages; diversify via next 10 docs; long-term contracts | CEO |
| 3 | Staff morale during freeze | Operational | ₹2 Cr | Medium | HIGH | Clear comms; protect performer increments; career pathing | CHRO |
| 4 | Vendor transition quality drop | Operational | ₹0.5 Cr | Medium | HIGH | 30-day overlap; SLA penalties; dual-vendor during transition | Admin Head |
| 5 | ARPOB growth slower than target | Commercial | ₹5 Cr | Medium | HIGH | Multiple levers (mix + pricing + insurance); not single-dependent | Dept Heads |
| 6 | Oracle Health delays | Technology | ₹1 Cr | High | MODERATE | Impact is Year 2; manual workarounds sufficient | CIO |
| 7 | Capex deferrals delay programs | Strategic | ₹3 Cr | Low | LOW | Only non-clinical deferred; clinical fully protected | CFO |
| 8 | Patient experience degradation | Operational | ₹1 Cr | Low | LOW | NPS monitoring; patient satisfaction surveys | COO |
🏛️ Single Weekly Review — Every Tuesday 8:00 AM
The entire 100-day plan is governed through one weekly review meeting every Tuesday. All 9 workstream owners present in a single 90-minute session. The CEO chairs, the CFO tracks financials. A 1-page scorecard is circulated by end-of-day Tuesday and escalations are resolved within 48 hours. Phase gates (Day 30, 60, 100) are held as extended sessions with Board attendance.
Tuesday Weekly Review — Structure
90 minutes · 9 workstreams · CEO chairs · Non-negotiable attendance
| Time | Agenda Item | Duration | Lead | Output |
|---|
| 8:00 | CFO opens — financial scorecard (savings locked vs pipeline vs at-risk) | 10 min | CFO | Live P&L impact tracker |
| 8:10 | Phase 1 workstreams: Vendor, Capex, Energy (RAG + blockers + asks) | 15 min | Admin / CFO / Procurement | Decision on escalations |
| 8:25 | Phase 2 workstreams: Doctor Fee, Staffing, Increment (RAG + blockers) | 20 min | CEO / CHRO | People actions approved |
| 8:45 | Phase 3 workstreams: ARPOB, OPD→IPD, Digital (RAG + KPIs) | 20 min | CEO / CIO / Revenue Cycle | Revenue metrics reviewed |
| 9:05 | Risk review — top 3 risks, mitigation status, new risks surfaced | 10 min | CEO | Risk register updated |
| 9:15 | CEO closes — decisions summary, week+1 priorities, any Board escalations | 15 min | CEO | Action items circulated by noon |
Tuesday Output
Same-day deliverables
→ 1-page scorecard (6 KPIs + RAG for all 9 workstreams)
→ Action items with owners and deadlines
→ Savings tracker: locked vs pipeline vs at-risk
→ Risk register update
→ Circulated to all leads + Board by 5 PM
Escalation Protocol
Between weekly reviews
→ Any RED status = CEO notified within 24 hours
→ Financial deviation > ₹50L = CFO escalation same-day
→ Doctor/clinical issues = Medical Director loop-in
→ Resolution expected within 48 hours of escalation
→ Unresolved items auto-escalate to Board
Phase Gates
Extended Tuesday sessions
Day 30 Gate: Vendor signed, capex frozen, doc model designed, hiring freeze in place
Day 60 Gate: 50+ FTEs absorbed, new hires on model, increment approved, ₹7+ Cr locked
Day 100 Gate: EBITDA ≥ 21%, People/Rev ≤ 35.5%, Staff/Bed ≤ 3.5x, ARPOB ≥ ₹53K, ₹18+ Cr validated
Workstream Ownership Matrix
Named individuals · No shared ownership · Weekly KPI reported at Tuesday review
| Workstream | Owner | Phase | Weekly KPI | Day 30 | Day 60 | Day 100 |
|---|
| Vendor Consolidation | Head - Admin | P1 | Vendor meetings held | Contracts signed | Savings in P&L | ₹1.5 Cr realised |
| Capex Freeze | CFO | P1 | POs reviewed | ₹3.5 Cr frozen | Committee running | Tracking embedded |
| Energy & Procurement | Head - Procurement | P1 | Audit progress | Quick-wins done | Formulary revised | ₹0.5 Cr realised |
| Doctor Fee Reform | CEO | P2 | Contracts reviewed | Model designed | New hires on model | Bottom-Q reviewed |
| Staffing Productivity | CHRO | P2 | FTE count | Freeze in place | 50 FTEs absorbed | 100 FTEs absorbed |
| Increment Reform | CHRO | P2 | Policy status | Policy drafted | Board approved | Budget updated |
| ARPOB Growth | CEO | P3 | ARPOB tracking | Baseline ₹49K | Clinics launched | ₹53K achieved |
| OPD→IPD Conversion | Revenue Cycle Lead | P3 | Conversion rate | Audit complete | CRM pilot live | 1% lift achieved |
| Digital / Oracle | CIO | P3 | Module progress | RFP finalised | Phase 1 kicked off | Billing live |